Google's Venture Capital Wing Invests In Biotech Company

email to a friend

printer friendly

opinions

Current Article Ratings:

Patient / Public:
Healthcare Prof:

Google's venture capital group is investing millions into Adimab, a biotech company that will construct a massive library of antibodies, some of which may yield powerful new drugs, the New York Times blog Bits reports. A Google Ventures executive said the company invests in "a variety of fields that don't necessarily directly correlate with Google products or services," but acknowledged that because "heavy-duty computation" is now a key part of biotech development, Google may collaborate with Adimab (Pollack, 10/1).

The executive also told Dow Jones VentureWire/Wall Street Journal, "Google Ventures has a pretty broad mandate." VentureWire reports "The firm, which invests for financial return, is considering opportunities in biotech, genomics, diagnostics and health care-IT, including the field of electronic medical records" (Gormley, 10/1).

This information was reprinted from kaiserhealthnews.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives and sign up for email delivery at kaiserhealthnews.org.

© Henry J. Kaiser Family Foundation. All rights reserved.

• Additional
• References
• Citations